REPORT ID 2092

Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Market Report 2017

Publish Date
7-Dec-17
Pages
105
Format
Electronic (PDF)

In this report, the Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Glucagon like peptide-1 (GLP-1) agonists for these regions, from 2012 to 2022 (forecast), including
    China
    Japan
    South Korea
    Taiwan
    India
    Southeast Asia
    Australia

Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists market competition by top manufacturers/players, with Glucagon like peptide-1 (GLP-1) agonists sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Novo Nordisk
    AstraZeneca
    Eli Lily
    GSK
    Sanofi
    Bristol-Myers Squibb
    Amylin
    ...

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Exenatied
    Liraglutide
    Lixisenatide
    Albiglutide
    Dulaglutide

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Glucagon like peptide-1 (GLP-1) agonists for each application, includin
    Hospital
    Pharmacy
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Market Report 2017
1 Glucagon like peptide-1 (GLP-1) agonists Overview
    1.1 Product Overview and Scope of Glucagon like peptide-1 (GLP-1) agonists
    1.2 Classification of Glucagon like peptide-1 (GLP-1) agonists by Product Category
        1.2.1 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Market Size (Sales) Comparison by Types (2012-2022)
        1.2.2 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Exenatied
        1.2.4 Liraglutide
        1.2.5 Lixisenatide
        1.2.6 Albiglutide
        1.2.7 Dulaglutide
    1.3 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Market by Application/End Users
        1.3.1 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Sales (Volume) and Market Share Comparison by Applications (2012-2022)
        1.3.2 Hospital
        1.3.3 Pharmacy
        1.3.4 Other
    1.4 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Market by Region
        1.4.1 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 China Status and Prospect (2012-2022)
        1.4.3 Japan Status and Prospect (2012-2022)
        1.4.4 South Korea Status and Prospect (2012-2022)
        1.4.5 Taiwan Status and Prospect (2012-2022)
        1.4.6 India Status and Prospect (2012-2022)
        1.4.7 Southeast Asia Status and Prospect (2012-2022)
        1.4.8 Australia Status and Prospect (2012-2022)
    1.5 Asia-Pacific Market Size (Value and Volume) of Glucagon like peptide-1 (GLP-1) agonists (2012-2022)
        1.5.1 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Sales and Growth Rate (2012-2022)
        1.5.2 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Revenue and Growth Rate (2012-2022)

2 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Competition by Players/Suppliers, Region, Type and Application
    2.1 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Market Competition by Players/Suppliers
        2.1.1 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share of Key Players/Suppliers (2012-2017)
        2.1.2 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Revenue and Share by Players/Suppliers (2012-2017)
    2.2 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists (Volume and Value) by Type
        2.2.1 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Sales and Market Share by Type (2012-2017)
        2.2.2 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Revenue and Market Share by Type (2012-2017)
    2.3 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists (Volume) by Application
    2.4 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists (Volume and Value) by Region
        2.4.1 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Sales and Market Share by Region (2012-2017)
        2.4.2 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Revenue and Market Share by Region (2012-2017)

3 China Glucagon like peptide-1 (GLP-1) agonists (Volume, Value and Sales Price)
    3.1 China Glucagon like peptide-1 (GLP-1) agonists Sales and Value (2012-2017)
        3.1.1 China Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Growth Rate (2012-2017)
        3.1.2 China Glucagon like peptide-1 (GLP-1) agonists Revenue and Growth Rate (2012-2017)
        3.1.3 China Glucagon like peptide-1 (GLP-1) agonists Sales Price Trend (2012-2017)
    3.2 China Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Type
    3.3 China Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Application

4 Japan Glucagon like peptide-1 (GLP-1) agonists (Volume, Value and Sales Price)
    4.1 Japan Glucagon like peptide-1 (GLP-1) agonists Sales and Value (2012-2017)
        4.1.1 Japan Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Growth Rate (2012-2017)
        4.1.2 Japan Glucagon like peptide-1 (GLP-1) agonists Revenue and Growth Rate (2012-2017)
        4.1.3 Japan Glucagon like peptide-1 (GLP-1) agonists Sales Price Trend (2012-2017)
    4.2 Japan Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Type
    4.3 Japan Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Application

5 South Korea Glucagon like peptide-1 (GLP-1) agonists (Volume, Value and Sales Price)
    5.1 South Korea Glucagon like peptide-1 (GLP-1) agonists Sales and Value (2012-2017)
        5.1.1 South Korea Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Growth Rate (2012-2017)
        5.1.2 South Korea Glucagon like peptide-1 (GLP-1) agonists Revenue and Growth Rate (2012-2017)
        5.1.3 South Korea Glucagon like peptide-1 (GLP-1) agonists Sales Price Trend (2012-2017)
    5.2 South Korea Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Type
    5.3 South Korea Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Application

6 Taiwan Glucagon like peptide-1 (GLP-1) agonists (Volume, Value and Sales Price)
    6.1 Taiwan Glucagon like peptide-1 (GLP-1) agonists Sales and Value (2012-2017)
        6.1.1 Taiwan Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Growth Rate (2012-2017)
        6.1.2 Taiwan Glucagon like peptide-1 (GLP-1) agonists Revenue and Growth Rate (2012-2017)
        6.1.3 Taiwan Glucagon like peptide-1 (GLP-1) agonists Sales Price Trend (2012-2017)
    6.2 Taiwan Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Type
    6.3 Taiwan Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Application

7 India Glucagon like peptide-1 (GLP-1) agonists (Volume, Value and Sales Price)
    7.1 India Glucagon like peptide-1 (GLP-1) agonists Sales and Value (2012-2017)
        7.1.1 India Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Growth Rate (2012-2017)
        7.1.2 India Glucagon like peptide-1 (GLP-1) agonists Revenue and Growth Rate (2012-2017)
        7.1.3 India Glucagon like peptide-1 (GLP-1) agonists Sales Price Trend (2012-2017)
    7.2 India Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Type
    7.3 India Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Application

8 Southeast Asia Glucagon like peptide-1 (GLP-1) agonists (Volume, Value and Sales Price)
    8.1 Southeast Asia Glucagon like peptide-1 (GLP-1) agonists Sales and Value (2012-2017)
        8.1.1 Southeast Asia Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Growth Rate (2012-2017)
        8.1.2 Southeast Asia Glucagon like peptide-1 (GLP-1) agonists Revenue and Growth Rate (2012-2017)
        8.1.3 Southeast Asia Glucagon like peptide-1 (GLP-1) agonists Sales Price Trend (2012-2017)
    8.2 Southeast Asia Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Type
    8.3 Southeast Asia Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Application

9 Australia Glucagon like peptide-1 (GLP-1) agonists (Volume, Value and Sales Price)
    9.1 Australia Glucagon like peptide-1 (GLP-1) agonists Sales and Value (2012-2017)
        9.1.1 Australia Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Growth Rate (2012-2017)
        9.1.2 Australia Glucagon like peptide-1 (GLP-1) agonists Revenue and Growth Rate (2012-2017)
        9.1.3 Australia Glucagon like peptide-1 (GLP-1) agonists Sales Price Trend (2012-2017)
    9.2 Australia Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Type
    9.3 Australia Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Market Share by Application

10 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Players/Suppliers Profiles and Sales Data
    10.1 Novo Nordisk
        10.1.1 Company Basic Information, Manufacturing Base and Competitors
        10.1.2 Glucagon like peptide-1 (GLP-1) agonists Product Category, Application and Specification
            10.1.2.1 Product A
            10.1.2.2 Product B
        10.1.3 Novo Nordisk Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue, Price and Gross Margin (2012-2017)
        10.1.4 Main Business/Business Overview
    10.2 AstraZeneca
        10.2.1 Company Basic Information, Manufacturing Base and Competitors
        10.2.2 Glucagon like peptide-1 (GLP-1) agonists Product Category, Application and Specification
            10.2.2.1 Product A
            10.2.2.2 Product B
        10.2.3 AstraZeneca Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue, Price and Gross Margin (2012-2017)
        10.2.4 Main Business/Business Overview
    10.3 Eli Lily
        10.3.1 Company Basic Information, Manufacturing Base and Competitors
        10.3.2 Glucagon like peptide-1 (GLP-1) agonists Product Category, Application and Specification
            10.3.2.1 Product A
            10.3.2.2 Product B
        10.3.3 Eli Lily Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue, Price and Gross Margin (2012-2017)
        10.3.4 Main Business/Business Overview
    10.4 GSK
        10.4.1 Company Basic Information, Manufacturing Base and Competitors
        10.4.2 Glucagon like peptide-1 (GLP-1) agonists Product Category, Application and Specification
            10.4.2.1 Product A
            10.4.2.2 Product B
        10.4.3 GSK Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue, Price and Gross Margin (2012-2017)
        10.4.4 Main Business/Business Overview
    10.5 Sanofi
        10.5.1 Company Basic Information, Manufacturing Base and Competitors
        10.5.2 Glucagon like peptide-1 (GLP-1) agonists Product Category, Application and Specification
            10.5.2.1 Product A
            10.5.2.2 Product B
        10.5.3 Sanofi Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue, Price and Gross Margin (2012-2017)
        10.5.4 Main Business/Business Overview
    10.6 Bristol-Myers Squibb
        10.6.1 Company Basic Information, Manufacturing Base and Competitors
        10.6.2 Glucagon like peptide-1 (GLP-1) agonists Product Category, Application and Specification
            10.6.2.1 Product A
            10.6.2.2 Product B
        10.6.3 Bristol-Myers Squibb Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue, Price and Gross Margin (2012-2017)
        10.6.4 Main Business/Business Overview
    10.7 Amylin
        10.7.1 Company Basic Information, Manufacturing Base and Competitors
        10.7.2 Glucagon like peptide-1 (GLP-1) agonists Product Category, Application and Specification
            10.7.2.1 Product A
            10.7.2.2 Product B
        10.7.3 Amylin Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue, Price and Gross Margin (2012-2017)
        10.7.4 Main Business/Business Overview
    ...

11 Glucagon like peptide-1 (GLP-1) agonists Manufacturing Cost Analysis
    11.1 Glucagon like peptide-1 (GLP-1) agonists Key Raw Materials Analysis
        11.1.1 Key Raw Materials
        11.1.2 Price Trend of Key Raw Materials
        11.1.3 Key Suppliers of Raw Materials
        11.1.4 Market Concentration Rate of Raw Materials
    11.2 Proportion of Manufacturing Cost Structure
        11.2.1 Raw Materials
        11.2.2 Labor Cost
        11.2.3 Manufacturing Expenses
    11.3 Manufacturing Process Analysis of Glucagon like peptide-1 (GLP-1) agonists

12 Industrial Chain, Sourcing Strategy and Downstream Buyers
    12.1 Glucagon like peptide-1 (GLP-1) agonists Industrial Chain Analysis
    12.2 Upstream Raw Materials Sourcing
    12.3 Raw Materials Sources of Glucagon like peptide-1 (GLP-1) agonists Major Manufacturers in 2016
    12.4 Downstream Buyers

13 Marketing Strategy Analysis, Distributors/Traders
    13.1 Marketing Channel
        13.1.1 Direct Marketing
        13.1.2 Indirect Marketing
        13.1.3 Marketing Channel Development Trend
    13.2 Market Positioning
        13.2.1 Pricing Strategy
        13.2.2 Brand Strategy
        13.2.3 Target Client
    13.3 Distributors/Traders List

14 Market Effect Factors Analysis
    14.1 Technology Progress/Risk
        14.1.1 Substitutes Threat
        14.1.2 Technology Progress in Related Industry
    14.2 Consumer Needs/Customer Preference Change
    14.3 Economic/Political Environmental Change

15 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Market Forecast (2017-2022)
    15.1 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Sales Volume, Revenue and Price Forecast (2017-2022)
        15.1.1 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Growth Rate Forecast (2017-2022)
        15.1.2 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Revenue and Growth Rate Forecast (2017-2022)
        15.1.3 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Price and Trend Forecast (2017-2022)
    15.2 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Sales Volume, Revenue and Growth Rate Forecast by Region (2017-2022)
        15.2.1 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Sales Volume and Growth Rate Forecast by Region (2017-2022)
        15.2.2 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Revenue and Growth Rate Forecast by Region (2017-2022)
        15.2.3 China Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.4 Japan Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.5 South Korea Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.6 Taiwan Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.7 India Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.8 Southeast Asia Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.9 Australia Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue and Growth Rate Forecast (2017-2022)
    15.3 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Sales, Revenue and Price Forecast by Type (2017-2022)
        15.3.1 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Sales Forecast by Type (2017-2022)
        15.3.2 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Revenue Forecast by Type (2017-2022)
        15.3.3 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Price Forecast by Type (2017-2022)
    15.4 Asia-Pacific Glucagon like peptide-1 (GLP-1) agonists Sales Forecast by Application (2017-2022)

16 Research Findings and Conclusion

17 Appendix
    17.1 Methodology/Research Approach
        17.1.1 Research Programs/Design
        17.1.2 Market Size Estimation